Replies to post #261 on Elan Corp PLC (ELN)

[blackcat]

The only thing we have done is ask him to report events correctly.

For instance, he reported that all ACC trials were halted. Not true. The US arm was suspended, the EU trial was not.

WYE has requested the FDA for permission to restart the US trial. The one patient in question did not have vasculitis.

regards,

Elaniacat

[DewDiligence]

>not sure what the "Elaniacs" as he calls them have said or done to Adam…<

Many of the posters on the iVillage board are certified nutcases. (Take a look at the posts about the blowout 1Q08 Copaxone results, for instance.)

[docbanker]

You have to ask yourself why ELN was trying for NTB in the first place and if the EMEA de-emphasizing it is a good thing.

One thing that confuses me is that bulls in this name say that starting a PIII trial automatically means the PII results at the interim look showed a "strong" trend. If this were the case, (i) why are the PIII trials well over 10x the size per arm and (ii) why in WYE's conference call did WYE CHANGE their reasoning for starting the PIIIs from (something like) only going to start it if PII were really good TO we are starting PIII b/c of (something like) encouraging trend, our immunology platform is great and there is a need for more drugs in the space (doesnt this sound watered down to you?)